Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (Nasdaq: SNDX) announced on October 1, 2025 that it granted inducement awards under its 2023 Inducement Plan to 10 new employees to purchase up to 138,900 shares of common stock. The awards are stock options that vest over four years: 25% vest on the one‑year anniversary of the vesting commencement date and the remaining shares vest monthly at 1/48th per month over the following 36 months, subject to continued service. The grants were reported under Nasdaq Listing Rule 5635(c)(4).
Syndax Pharmaceuticals (Nasdaq: SNDX) ha annunciato il 1 ottobre 2025 di aver concesso premi di induzione ai sensi del 2023 Inducement Plan a 10 nuovi dipendenti per l'acquisto di al massimo 138.900 azioni ordinarie. I premi sono stock option che vestono nel corso di quattro anni: il 25% vestisce al compimento di un anno dalla data di inizio della vesting e le restanti azioni vestono mensilmente a 1/48 al mese nei 36 mesi successivi, soggetti a continuo servizio. Le concessioni sono state riportate ai sensi della Nasdaq Listing Rule 5635(c)(4).
Syndax Pharmaceuticals (Nasdaq: SNDX) anunció el 1 de octubre de 2025 que otorgó premios por inducción bajo su Plan de Inducción 2023 a 10 nuevos empleados para comprar hasta 138,900 acciones comunes. Los premios son opciones sobre acciones que se consolidan/vesten durante cuatro años: el 25% se consolida al cumplirse un año desde la fecha de inicio de la consolidación y las acciones restantes se consolidan mensualmente a 1/48 por mes durante los 36 meses siguientes, sujeto a la prestación continua de servicios. Las concesiones se reportaron de acuerdo con la Nasdaq Listing Rule 5635(c)(4).
Syndax Pharmaceuticals (Nasdaq: SNDX)는 2025년 10월 1일 2023 Inducement Plan에 따라 새로운 10명의 직원에게 최대 138,900주의 보통주를 매입할 수 있도록 유인 보상을 부여했다고 발표했습니다. 보상은 4년에 걸쳐 vesting되는 주식매수선택권으로, 기산일로부터 1년 차에 25%가 vest되고 남은 주식은 이후 36개월 동안 매달 1/48씩 vest되며, 지속적인 서비스가 전제됩니다. 이번 부여는 Nasdaq Listing Rule 5635(c)(4)에 따라 보고되었습니다.
Syndax Pharmaceuticals (Nasdaq : SNDX) a annoncé le 1er octobre 2025 avoir accordé des récompenses d'incitation dans le cadre de son Plan d'induction 2023 à 10 nouveaux employés afin d'acheter jusqu'à 138 900 actions ordinaires. Les récompenses sont des options d'achat d'actions qui se consolident sur quatre ans : 25% se consolident à l'anniversaire d'un an à compter de la date de début de la consolidation et les actions restantes se consolident mensuellement à 1/48 par mois au cours des 36 mois suivants, sous réserve de la poursuite du service. Les attributions ont été signalées conformément à la Nasdaq Listing Rule 5635(c)(4).
Syndax Pharmaceuticals (Nasdaq: SNDX) kündigte am 1. Oktober 2025 an, dass es Anreize im Rahmen seines 2023 Inducement Plan an 10 neue Mitarbeiter gewährt hat, um bis zu 138.900 Stammaktien zu erwerben. Die Zuwendungen bestehen aus Aktienoptionsrechten, die über vier Jahre vesten: 25% vesten am einjährigen Jubiläum des Vesting-Beginns und die verbleibenden Anteile vesten monatlich mit 1/48 pro Monat über die folgenden 36 Monate, vorbehaltlich fortgesetzter Tätigkeit. Die Zuwendungen wurden gemäß Nasdaq Listing Rule 5635(c)(4) gemeldet.
Syndax Pharmaceuticals (بورصة ناسداك: SNDX) أعلنت في 1 أكتوبر 2025 أنها منحت جوائز حافز بموجب خطة التحفيز 2023 لـ10 موظفين جدد لشراء حتى 138,900 سهماً عادياً. الجوائز هي خيارات أسهم تقيد خلال أربع سنوات: يتقيد 25% عند الذكرى السنوية لسنة بدء التقييد وتتصاعد الأسهم المتبقية شهرياً بمعدل 1/48 شهرياً خلال الـ 36 شهراً التالية، رهناً بالخدمة المستمرة. تم الإبلاغ عن المنح بموجب قاعدة إدراج ناسداك 5635(c)(4).
Syndax Pharmaceuticals (纳斯达克：SNDX) 于 2025 年 10 月 1 日宣布，根据其 2023 Inducement Plan 向 10 名新员工授予诱导性奖励，以购买最多 138,900 股普通股。该奖励是股票期权，按 四年 的时间表 vest：在 vesting 开始日期满一周年时 vest 25%，其余部分在随后的 36 个月内每月以 1/48 的比例 vest，前提为持续服务。该授予依据 Nasdaq Listing Rule 5635(c)(4) 进行了披露。
- None.
- None.
NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2025 the Company granted inducement awards to purchase up to 138,900 shares of common stock to 10 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
FAQ
What did Syndax (SNDX) announce on October 1, 2025 regarding inducement grants?
How do the SNDX inducement options vest and when do they start vesting?
Under which Nasdaq rule did Syndax report the October 1, 2025 inducement awards?
How many employees received inducement awards in the Syndax October 2025 grant?
Are the Syndax inducement awards part of an existing plan and which one?
Do the inducement grants immediately dilute SNDX shares after October 1, 2025?
